Beth Fand Incollingo

The investigational drug sotorasib demonstrated promising antitumor activity in patients with non-small cell lung cancer that harbor the KRAS p.G12C mutation, an aberration for which no targeted treatment has yet been approved.

When added to bortezomib and dexamethasone in patients with multiple myeloma, selinexor, an inhibitor of XPO1-mediated nuclear export, improves progression-free survival and overall response rate and reduces the incidence of peripheral neuropathy.

The cancer mortality rate declined more in states that expanded Medicaid coverage than those that didn’t following the passage of the Affordable Care Act of 2010, a study found.

Women who took part in a supervised exercise program during adjuvant treatment for breast cancer had better cardiovascular function than women who did not participate in the program.

Losing even some extra weight significantly reduces the risk of breast cancer for postmenopausal women, expert says.

Women who have had early breast cancer, along with their doctors, often worry that pregnancy could cause disease recurrence. But according to the results of a new study, that’s not the case.

The rate of severe long-term side effects caused by treatments for childhood cancers is dropping over time, according to findings from a retrospective analysis of 23,600 survivors enrolled in the Childhood Cancer Survivor Study.

Patients with stage III colorectal cancer who maintained a healthy body weight, engaged in regular physical activity, and adopted other healthy lifestyle behaviors experienced a 42% lower chance of death and a trend toward reduced cancer recurrence.

While mutations of the BRCA gene can increase a woman’s chances of developing breast and ovarian cancers, the presence of the gene made no difference in survival for women aged 40 years or younger who were diagnosed with early-stage breast cancer.

Adding temozolomide to short-course radiotherapy after surgery boosted overall survival by nearly 2 months, bringing 1-year survival rates up from 22.2% to 37.8% for elderly patients with glioblastoma.

The addition of capecitabine to standard adjuvant gemcitabine doubled 5-year overall survival (OS) rates for patients with pancreatic cancer whose tumors were surgically removed.

When chemotherapy involves tricky infusion timing, patients are routinely admitted to hospitals to receive their treatments. But what would happen if these drugs could be administered successfully on an outpatient basis?

Lots of people take their work home with them, but Lynne Malestic, RN, has given the idea new meaning.

The possibility that hospitalized cancer patients will fall is an ongoing concern among the medical professionals who care for them.

Targeted agents, particularly ibrutinib and idelalisib, are becoming increasingly important in the treatment of chronic lymphocytic leukemia, and have replaced chemotherapy in many settings.

With the R-CHOP chemotherapy regimen considered the backbone of therapy for treatment-naïve patients with non-Hodgkin lymphoma, researchers are now delving further into the genome to pave the way for therapeutic improvements.

Ibrutinib sparks more durable remissions than temsirolimus in patients with relapsed or refractory mantle cell lymphoma.

Ibrutinib reduced the risk of death by 84% versus chlorambucil in treatment-naïve elderly patients with chronic lymphocytic leukemia.

Ruxolitinib continues to demonstrate sustained benefits for patients with myelofribrosis in a 5-year follow-up of the phase III COMFORT-II study.

Over the past 30 years, survivors of childhood cancers have become less likely to die of illnesses caused by their treatment, such as new malignancies or cardiac or lung disease.

A biomarker has been found that may help determine which Gleason 7 (GS7) cancers are particularly aggressive.

One-third of men over 70 years of age who undergo radical prostatectomy for prostate cancer and then experience biochemical recurrence have no need for salvage treatment, according to a recent study.

Fats in blood and on the body increase men's prostate cancer risk, two studies have found.

The use of multiparametric MRI in diagnosing and treating prostate cancer was explored in November during a continuing medical education course offered at the annual meeting of LUGPA

The novel drug AG-221 generated durable remissions in patients with AML by targeting a mutation of the IDH2 gene in a small, first-in-man study that represents a new, chemotherapy-free approach for attacking the malignancy.

Patients with relapsed and difficult-to-treat Hodgkin lymphoma who received brentuximab vedotin had an unprecedented 50% higher likelihood of continuing to experience PFS at 2 years.

In a small phase I trial, most patients with classical Hodgkin lymphoma, having previously failed three or more therapies, responded to the immunotherapy nivolumab.

From a limited first meeting in the late 1990s that included the leaders of a dozen large group practices, LUGPA has grown so much that its annual meeting this November will include up to 550 physicians and 200 administrators, filling the organization's usual Chicago venue to capacity and necessitating a move to a larger space next year.

A round-up of new drugs that are being investigated as treatments for genitourinary cancers.

Despite the promise associated with biomarker-based tools as a means of helping to guide cancer diagnosis and treatment, there is a potential stumbling block: insurance reimbursement.